Recently, in KYinno Biotechnology (Beijing) Co, staff members are busy with R&D projects.

A staff member of KYinno records data. [Photo/beijingetown.com.cn]

Peng Hao, co-founder and deputy general manager of KYinno, remarked that, "With the introduction of new measures for epidemic prevention and control, the company's employees have basically returned to work. Now, more than 10 platforms and R&D projects are being carried out in an orderly and synchronous manner." 

"Currently, one of our key projects, the multiple myeloma new medicine project, is progressing steadily and is expected to enter the clinical stage next year," Peng added.

Beijing Yizhuang Biomedical Park, where KYinno is located, has a full-chain biomedical technology service platform integrating the five major service systems: space carrier, technical service, capital operation, professional talents and industrial policy. 

The park not only enables enterprises to get settled quickly, its service scope also covers the whole life cycle of the development of biomedical innovation enterprises. 

"In the past six months, the park has reduced our rent by 50 percent, allowing us to have more funds to invest in research and development," said Peng.

As the leading industry in Beijing E-Town, the biomedicine and big health industry has formed a 100 billion-level industrial cluster. Beijing E-Town not only opens up a green channel for customs clearance through the construction of Bio-Platform Logistics Service Center, but also creates high-quality biopharmaceutical companies.

After settling in Beijing E-Town in 2017, KYinno has built the industry's largest gene-edited cell bank in just five years to help the development of new tumor drugs. With its unique double antibody technology platform, artificial intelligence and other technologies, it greatly shortens the cycle of medicine development and antibody discovery.

"We are quite confident about the next development. This year's annual output value is expected to increase by more than 60 percent compared with last year. In the next 2 to 3 years, as the first and second phases of new drugs enter clinical and more commercial transfers of products, we expect to double our revenue," Peng added.